Measles Partnership Meeting Update on Vaccine Supply

1
Measles Partnership MeetingUpdate on Vaccine
Supply
Washington, 27-28th February 2007 UNICEF Supply
Division
2
UNICEF procures immunization supplies on behalf
of 80-100 countries Vaccines, Injection Devices,
Cold Chain (BCG , DTP, TT/Td/DT, Measles, OPV,
HepB, YF, DTP-HepB, DTP-HepBHib, DTP-Hib, MR,
Meningitis, MMR, IPV, Rabies, J.E., etc) - 2006
immunization supply expenditures USD 550M
(including cold chain)- Over 3.0 billion doses
of vaccine, over 900 million AD syringes-
1,800 vaccine shipments
Countries UNICEF procures on behalf of
All Vaccines
Part of the Vaccines
3
A significant proportion of low income country
vaccine needs are met through UNICEF procurement
Data Sources Population Data The State of the
Worlds Children 2006 Procurement Coverage Data
UNICEF Vaccine Forecast 2006 Income
Classification World Bank
4
Vaccine Security Ensuring the uninterrupted
sustainable supply of affordable quality
vaccines, remains the principle driver of UNICEF
Vaccine Supply

• Vaccine Procurement Principles
• A healthy industry is vital to ensure an
  uninterrupted and sustainable supply of vaccines
• Procurement from multiple suppliers for each
  vaccine presentation
• Paying a price that is affordable to Governments
  and Donors and a price that reasonably covers
  manufacturers minimum requirements

• Three Pillars of Vaccine Security
• Appropriate Contracting
• Firm Funding
• Accurate Forecasting

5
Vaccine Security remains a critical issue
Positive trends are seen in the new markets
Market development- Positive trends lead by HepB
market Critical Stage of Introduction of
DTP-HepB and DTP-HepBHib Principles of Vaccines
Security remain valid - to ensure a Healthy Market
HepB
DTP-HepB
DTP-HepB/Hib
6
However in the mature traditional vaccine markets
although there has been progress made.
BCG
DTP
Measles
TT
7
there is less Vaccine Security - increased
dependency on fewer manufacturers for a growing
demand
Number of manufacturers per vaccine
Current Awards
8
Overview of Measles demandGrowth in Measles
demand 1996 - 2006
Significant growth in the Quantity of Vaccines
Procured
9
UNICEF Measles procurement profile
Routine Demand relatively stable, Supplementary
activities make up majority of demand largest
impact on forecast quantities 2006 peak year,
large campaigns undertaken, challenging logistics
10
Looking towards the 2010 GoalEnsuring Supply for
2007 2010
Data as at time of Tender Activities
Bidding Activities 2006 - Supply Arrangements in
place 2007 2009 Offered quantities sufficient
to meet the forecasted demand requirements
11

However in terms of Vaccine Security the supply
is still at risk .
High dependence (75 of award) on one supplier
for Measles vaccine for 2007 Reduction in the
number of suppliers awarded due to reduced number
of WHO pre-qualified offers received.
12
Responses to the RFP for the 2007 2009 supply
indicated potential new suppliers for measles
vaccine
Measles containing vaccines are classified as
high priority for WHO pre-qualification New
suppliers would create a more secure market
13
Awards made for full forecast demand quantity in
2007
14
Overview of Measles Vaccine Supply 2007
Based on current information, sufficient supply
to meet the demand
Dynamic situation large Campaigns have a
significant impact
15
Impact of changed schedule of Pakistan Campaign
No Date of Campaign Target Qty Delivery Date 5
Phases 1 March 2007 2,607,785 Delivered 2 J
uly 2007 9,066,827 June 2007 3 Aug/Sep
2007 6,730,182 July 2007 4 Nov
2007 15,880,000 Sep/Oct 2007 5 Mar
2008 39,143,000 Nov/Dev 2007
16
Overview of MR Vaccine Demand

• Historically limited quantities procured by
  UNICEF
• High variance in demand due to intermittent
  campaign procurement
• Current Supply Arrangements covered forecasted
  demand at time of Tender

• New Campaign Activities forecast for Q4 2007
• Tender issued, closing 5th March 2007
• Tight Supply Situation, 2 Suppliers

17
Overview of MMR Vaccine Market

• UNICEF demand for this vaccine is low.
• Current Supply Arrangements covered forecasted
  demand at time of Tender
• No JL strain available to UNICEF currently
• Product is difficult to manage due to strain
  preferences from Countries and limited available
  pre-qualified products.

18
As a Partnership, what can we do to ensure
Improved Vaccine Security?

• Continue the Partnership
• Accurate Forecasting
• Early/ Long Term Campaign Planning particularly
  Large Campaigns
• Quantities and Timing of Demand
• Need to assess the overall market demand
  including other Procuring Agencies and India
  Campaign Activities
• In Country Logistics in place
• Firm Funding
• Secure Sufficient Funding to meet program goals
  2007 - 2010
• Early Funds Transfer
• Support Vaccine Security
• Appropriate Contracting
• Ensure Adequate Contracts in place
• Expand the Supply Base

19
Thank You !